1448902-04-2

Upstream product

• 100-51-6 benzyl alcohol 
• 534572-20-8 (3S,5R)-1-(tert-butoxycarbonyl)-3-(methoxycarbonyl)piperidine-5-carboxylic acid 
• 914260-44-9 2,4-dioxo-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylic acid tert-butyl ester 
• 920297-39-8 1-(tert-butoxycarbonyl)piperidine-3,5-dicarboxylic acid 
• 4591-55-3 dimethyl pyridine-3,5-dicarboxylate 
• 499-81-0 3,5-Pyridinedicarboxylic acid 

Downstream Products

• 1448902-11-1 tert-butyl (3R,5S)-3-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-1-(3-chlorophenyl)propyl]carbamoyl}piperidine-1-carboxylate 
• 1448902-12-2 tert-butyl (3R,5S)-3-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-1-(4-chlorophenyl)propyl]carbamoyl}piperidine-1-carboxylate 
• 1263198-31-7 tert-butyl (3R,5S)-3-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-1-(5-fluoro-2-pyridyl)-3-methylbutyl]carbamoyl}piperidine-1-carboxylate 
• 1448902-13-3 tert-butyl (3R,5S)-3-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-1-(5-fluoro-3-pyridyl)-3-methylbutyl]carbamoyl}piperidine-1-carboxylate 
• 1448902-14-4 tert-butyl (3R,5S)-3-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-1-isoxazol-5-yl-3-methylbutyl]carbamoyl}piperidine-1-carboxylate 
• 1448902-15-5 tert-butyl (3R,5S)-3-[4-(2-chlorophenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-3-methyl-1-oxazol-2-yl-butyl]carbamoyl}piperidine-1-carboxylate 
• 1263198-51-1 tert-butyl (3R,5S)-3-[2,2-dimethyl-4-(o-tolyl)-5-oxopiperazin-1-yl]-5-{[(1R)-1-(5-fluoro-2-pyridyl)-3-methylbutyl]carbamoyl}piperidine-1-carboxylate 
• 1263198-71-5 tert-butyl (3R,5S)-3-[4-(5-fluoro-2-methylphenyl)-2,2-dimethyl-5-oxopiperazin-1-yl]-5-{[(1R)-1-(5-fluoro-2-pyridyl)-3-methylbutyl]carbamoyl}piperidine-1-carboxylate 

Relevant academic research and scientific papers

Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity

With approximately 37 million people living with HIV worldwide and an estimated 2 million new infections reported each year, the need to derive novel strategies aimed at eradicating HIV-1 infection remains a critical worldwide challenge. One potential strategy would involve eliminating infected cells via antibody-dependent cellular cytotoxicity (ADCC). HIV-1 has evolved sophisticated mechanisms to conceal epitopes located in its envelope glycoprotein (Env) that are recognized by ADCC-mediating antibodies present in sera from HIV-1 infected individuals. Our aim is to circumvent this evasion via the development of small molecules that expose relevant anti-Env epitopes and sensitize HIV-1 infected cells to ADCC. Rapid elaboration of an initial screening hit using parallel synthesis and structure-based optimization has led to the development of potent small molecules that elicit this humoral response. Efforts to increase the ADCC activity of this class of small molecules with the aim of increasing their therapeutic potential was based on our recent cocrystal structures with gp120 core.

SMALL MOLECULES THAT SENSITIZE HIV-1 INFECTED CELLS TO ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY

Compounds and methods of treating HIV-1 in a human infected with HIV-1 or preventing HIV-1 infection in a human susceptible to infection with HIV-1 are provided. The compounds are of formula (I), (II), and (IA), wherein R1-R7, X, X', Y, Y', Z, and n are defined herein, and the methods comprises administering therapeutically effective amounts of these compounds to the human.

Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4- phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors

We report synthesis and optimization of a series of (3S,5R)-5-(2,2- dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as renin inhibitors. Chemical modification of P1, P2 and P 3 portions led to a promising 3